Journal of Pharmacoeconomics and Pharmaceutical Management 2016. 2(1/2):30-33.

Cost-effectiveness analysis of cinacalcet versus vitamin D analogs in secondary hyperparathyroidism in end-stage renal disease patients on dialysis (Protocol)
Nilofar Sharahi, Majid Davari, Tahereh Malakoutian, Zahra Gharibnaseri


Background: Chronic kidney disease (CKD) is an irreversible and progressive deterioration of renal function. The terminate stage of CKD is known as end-stage renal disease (ESRD) at which the patient needs a renal replacement therapy such as dialysis. Secondary hyperparathyroidism (SHPT) - excessive production of parathyroid hormone - is a common complication of impaired renal function. Patients with ESRD are likely at high risk for varying degrees of SHPT. Guidelines recommend pharmacotherapy as the main treatment of SHPT. Cinacalcet is a new medicine for treating patients with SHPT. The aim of this paper was to describe the background, rationale, objectives, design, and methodology of cost-effectiveness analysis of cinacalcet for SHPT in ESRD patients.
Methods: We will perform a systematic review of the approved databases and literature to collect randomized control trials on SHPT. The definitions, data sources, methods of data gathering, and data generating will be explained in this paper. One-way sensitivity analysis will be used for estimating the robustness of our results.
Conclusion: This study helps to obtain information concerning the cost-effectiveness of using cinacalcet in the treatment regimen of SHPT patients. The result will assist policy makers and physicians to support the most cost-effective pharmaceutical therapy for SHPT patients. This would increase allocative efficiency of the health-care delivery system in Iran.


End-stage renal disease; Secondary hyperparathyroidism; Cinacalcet; Cost-effectiveness

Full Text:



(1) Garside R, Pitt M, Anderson R, Mealing S, Roome C, Snaith A, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess 2007; 11(18): iii, xi-iii,167.

(2) National Institute for Health and Care Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy [Online]. [cited 2007 Jan 24]; Available from: URL:

(3) U.S.Food and Drug Administration. Sensipar (cinacalcet) Tablets [Online]. [cited 2014]; Available from: URL:

(4) Darryl Quarles L, Berkoben M. Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients [Online]. [cited 2015 Sep

; Available from: URL:

(5) Li D, Shao L, Zhou H, Jiang W, Zhang W, Xu Y. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis. Endocrine 2013; 43(1): 68-77.

(6) Bellasi A, Cozzolino M. Cinacalcet: the chemical parathyroidectomy? Clin Kidney J 2013; 6(3): 253-6.

(7) Ballinger AE, Palmer SC, Nistor I, Craig JC, Strippoli GF. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2014; (12): CD006254.

(8) Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: John Wiley & Sons; 2011.

(9) Hruska KA, Teitelbaum SL. Renal Osteodystrophy. N Engl J Med 1995; 333: 166-75.

(10) Longo D, Fauci A, Kasper D, Hauser S, Jameson J, Loscalzo J. Harrison's Principles of Internal Medicine. New York, NY: McGraw Hill Professional; 2011.

(11) Aghighi M, Mahdavi-Mazdeh M, Zamyadi M, Heidary Rouchi A, Rajolani H, Nourozi S. Changing epidemiology of end-stage renal disease in last 10 years in Iran. Iran J Kidney Dis 2009; 3(4): 192-6.

(12) Chow FY, Briganti EM, Kerr PG, Chadban SJ, Zimmet PZ, Atkins RC. Health-related quality of life in Australian adults with renal insufficiency: a population-based study. Am J Kidney Dis 2003; 41(3): 596-604.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.